2 completed, 2 recruiting, 1 not yet recruiting, 1 terminated. 2 Phase 2, 1 Not applicable, 1 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 1, Terminated 1 |
| Not applicable | 1 | Completed 1 |
| Phase 1 | 1 | Terminated 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow this condition Literature Review of Anti-MAG Neuropathy trials Research Report on Anti-MAG Neuropathy
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study Evaluating the Predictive Value of the Terminal Latency Index (TLI) for Treatment Response in Patients With Anti-MAG Neuropathy Electroneuromyography (ENMG) and Terminal Latency Index (TLI) Assessment - Anti-MAG Neuropathy, Peripheral Nervous System Disease | Not yet recruiting | Centre Hospitalier Universitaire de Nice | 100 | 2026-09-01 | 2026-08-31 | |
| Studying Nerve Function and Structure in Charcot-Marie-Tooth Disease, Anti-MAG Neuropathy and CIDP Charcot-Marie-Tooth, CMT1A | Recruiting | Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta | 39 | 2025-03-03 | 2026-03-10 | |
| Rituximab Therapy in Anti-Myelin Associated Glycoprotein Patients With Characteristics of Good Responders Rituximab infusion, Placebo infusion, Premedications - Anti-MAG Neuropathy | Phase 3 | Recruiting | Centre Hospitalier Universitaire de Saint Etienne | 90 | 2023-06-29 | 2025-11-24 |
| First in Human Study to Test the Safety and Preliminary Efficacy of PPSGG in Patients With Anti-MAG Neuropathy PPSGG, Placebo - Anti-MAG Neuropathy | Phase 1 / Phase 2 | Terminated | Polyneuron Pharmaceuticals AG | 1 | 2020-11-17 | 2021-10-15 |
| Quantification of Nerve Stiffness in Neuropathies elastography measurements - Chronic Inflammatory Demyelinating Polyneuropathy, Charcot-Marie-Tooth Disease, Type IA | Not applicable | Completed | Nantes University Hospital | 36 | 2018-04-11 | 2026-09-14 |
| SERENDEM : MD1003 in Patients Suffering From Demyelinating Neuropathies, an Open Label Pilot Study MD1003 - Chronic Inflammatory Demyelinating Polyneuropathy, Peripheral Neuropathy | Phase 2 | Completed | MedDay Pharmaceuticals SA | 15 | 2016-12-05 | 2020-11-02 |
Charcot-Marie-Tooth Disease (3) · Peripheral Nervous System Diseases (3) · Polyradiculoneuropathy, Chronic Inflammatory Demyelinating (3) · Charcot-Marie-Tooth disease, Type 4B2 (1) · Charcot-Marie-Tooth disease, X-linked, 1 (1) · Neuropathy, hereditary motor and sensory, LOM type (1)
Nervous System Diseases (5) · Neuromuscular Diseases (5) · Autoimmune Diseases (3) · Autoimmune Diseases of the Nervous System (3) · Chronic Disease (3) · Congenital Abnormalities (3) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (3) · Demyelinating Diseases (3) · Disease Attributes (3) · Genetic Diseases, Inborn (3) · Hereditary Sensory and Motor Neuropathy (3) · Heredodegenerative Disorders, Nervous System (3) · Immune System Diseases (3) · Nervous System Malformations (3) · Neurodegenerative Diseases (3)
Biotin (1) · Physical Examination (1) · Premedication (1) · Rituximab (1) · Sodium Chloride (1)
Centre Hospitalier Universitaire de Nice (1) · Centre Hospitalier Universitaire de Saint Etienne (1) · Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta (1) · MedDay Pharmaceuticals SA (1) · Nantes University Hospital (1) · Polyneuron Pharmaceuticals AG (1)
France (5) · Italy (1) · Netherlands (1) · Spain (1) · Switzerland (1) · United Kingdom (1)
Davide Pareyson, MD (1) · Frederic Sedel, MD (1) · Hedvika Lazar (1) · Mecheli Cavalli (1) · Yann Pereon, PU-PH (1)